2023
Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.
Shatsky R, Thomas A, Yau C, Chien A, Falkson C, Stringer-Reasor E, Omene C, Trivedi M, Boughey J, Sanford A, Arora M, Sanft T, Nanda R, Isaacs C, Brown T, Hylton N, DeMichele A, Yee D, Esserman L. Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL. Journal Of Clinical Oncology 2023, 41: lba612-lba612. DOI: 10.1200/jco.2023.41.17_suppl.lba612.Peer-Reviewed Original ResearchImmune related adverse eventsWeeks x 4High-risk breast cancerPD-1 inhibitorsPathologic complete responseOral paclitaxelPeripheral neuropathyControl armBreast cancerRates of neutropeniaEfficacy of immunotherapyPhase 2 trialRelated adverse eventsHigh-risk cancerBiomarker subtypesI-SPY2Neoadjuvant agentWeekly trastuzumabOral agentsPrimary endpointAdverse eventsComplete responseOral combinationCombination therapyPump inhibitors
2018
Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint
Boughey JC, Alvarado MD, Lancaster RB, Fraser Symmans W, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Godellas C, Chen M, Kalinsky K, Hibshoosh H, Killelea B, Sanft T, Hirst G, Asare S, Matthews J, Perlmutter J, Esserman L, and I-SPY 2 Investigators. Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint. Npj Breast Cancer 2018, 4: 26. PMID: 30131975, PMCID: PMC6098077, DOI: 10.1038/s41523-018-0074-6.Peer-Reviewed Original ResearchAxillary lymph node dissectionLymph node dissectionClinical trialsNeoadjuvant chemotherapyNode dissectionPositive diseaseDrug therapy trialsI-SPY2 trialManagement of axillaBreast cancer clinical trialsNode-positive diseaseProspective clinical trialsMulticenter clinical trialAssessment of responseClinical trial dataCancer clinical trialsNeoadjuvant settingPrimary endpointNodal involvementSurgical resectionSurgical managementProper stagingResidual diseaseSurgical standardAxilla